Poxviral vectors for cancer immunotherapy

Bibliography

• Moss B, Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol 1987;5:305-24
   PubMed Web of Science ®Google Scholar
• Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011;239:8-26
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Hruby DE. Biology of vaccinia virus acylproteins. Front Biosci 1998;3:d354-64
   Google Scholar
• Tsang KY, Zaremba S, Nieroda CA, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90
   PubMed Web of Science ®Google Scholar
• Gulley J, Chen AP, Dahut W, Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53:109-17
   PubMed Web of Science ®Google Scholar
• Weli SC, Tryland M. Avipoxviruses: infection biology and their use as vaccine vectors. Virol J 2011;8:49
   PubMed Web of Science ®Google Scholar
• Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993;197:439-44
   PubMed Web of Science ®Google Scholar
• Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-68
   PubMed Web of Science ®Google Scholar
• Bernards R, Destree A, McKenzie S, Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987;84:6854-8
   PubMed Web of Science ®Google Scholar
• Lathe R, Kieny MP, Gerlinger P, Tumour prevention and rejection with recombinant vaccinia. Nature 1987;326:878-80
   PubMed Web of Science ®Google Scholar
• Hareuveni M, Gautier C, Kieny MP, Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 1990;87:9498-502
   PubMed Web of Science ®Google Scholar
• Meneguzzi G, Kieny MP, Lecocq JP, Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. Vaccine 1990;8:199-204
   PubMed Web of Science ®Google Scholar
• Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991;48:900-7
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992;52:6917-25
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91
   PubMed Web of Science ®Google Scholar
• Mackett M, Smith GL, Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 1984;49:857-64
   PubMed Web of Science ®Google Scholar
• Sanda MG, Smith DC, Charles LG, Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999;53:260-6
   PubMed Web of Science ®Google Scholar
• Eder JP, Kantoff PW, Roper K, A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6:1632-8
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA, Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J, Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122-32
   PubMed Web of Science ®Google Scholar
• Kaufman H, Wang W, Manola J, Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897. J Clin Oncol 2005;23(16S):abstract 4501
   Google Scholar
• Boehm AL, Higgins J, Franzusoff A, Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother 2010;59:397-408
   PubMed Web of Science ®Google Scholar
• Hodge JW, Higgins J, Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine 2009;27:4475-82
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Todd N, Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;174:539-46
   PubMed Web of Science ®Google Scholar
• Lechleider RJ, Arlen PM, Tsang KY, Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284-91
   PubMed Web of Science ®Google Scholar
• Horig H, Lee DS, Conkright W, Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14
   PubMed Web of Science ®Google Scholar
• von Mehren M, Arlen P, Tsang KY, Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219-28
   PubMed Web of Science ®Google Scholar
• Savage CO, Hughes CC, Pepinsky RB, Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4+ T cells. Cell Immunol 1991;137:150-63
   PubMed Web of Science ®Google Scholar
• Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992;148:1985-92
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J, Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61:3725-34
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7
   PubMed Web of Science ®Google Scholar
• Tatari-Calderone Z, Semnani RT, Nutman TB, Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J Immunol 2002;169:6162-9
   PubMed Web of Science ®Google Scholar
• Zhou J, Tagaya Y, Tolouei-Semnani R, Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs. Blood 2005;105:3238-46
   PubMed Web of Science ®Google Scholar
• Oh S, Hodge JW, Ahlers JD, Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol 2003;170:2523-30
   PubMed Web of Science ®Google Scholar
• Hodge JW, Chakraborty M, Kudo-Saito C, Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174:5994-6004
   PubMed Web of Science ®Google Scholar
• Yang S, Schlom J. Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. Cancer Immunol Immunother 2009;58:503-15
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM, Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Cohen S, Cheung K, Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 2006;17:239-44
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 2007;7:543-54
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001-11
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M, Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178:1515-20
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253:328-35
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Haining WN, Davies J, Kanzler H, CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008;14:5626-34
   PubMed Web of Science ®Google Scholar
• Kass E, Panicali DL, Mazzara G, Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen Q, Morris L, Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 2006;29:499-511
   PubMed Web of Science ®Google Scholar
• Igartua M, Pedraz JL. Topical resiquimod: a promising adjuvant for vaccine development? Expert Rev Vaccines 2010;9:23-7
   PubMed Web of Science ®Google Scholar
• Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401-4
   PubMed Web of Science ®Google Scholar
• Dreicer R, Stadler WM, Ahmann FR, MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009;27:379-86
   PubMed Web of Science ®Google Scholar
• Quoix E, Ramlau R, Westeel V, Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12:1125-33
   PubMed Web of Science ®Google Scholar
• Melchionda F, Fry TJ, Milliron MJ, Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005;115:1177-87
   PubMed Web of Science ®Google Scholar
• Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68
   PubMed Web of Science ®Google Scholar
• Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 2007;104:588-93
   PubMed Web of Science ®Google Scholar
• Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005;32:537-48
   PubMed Web of Science ®Google Scholar
• Parato KA, Breitbach CJ, Le Boeuf F, The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2011 Dec 20 [Epub ahead of print]
   Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42
   PubMed Web of Science ®Google Scholar
• Higano CS, Saad F, Somer B, A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. ASCO Genitourinary Cancers Symposium 2009
   Google Scholar
• Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996;184:1-8
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94
   PubMed Web of Science ®Google Scholar
• Nesslinger NJ, Sahota RA, Stone B, Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493-502
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Tsang KY, A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 2011;11:1409-18
   PubMed Web of Science ®Google Scholar
• Matsuzaki I, Suzuki H, Kitamura M, Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 2000;59:336-43
   PubMed Web of Science ®Google Scholar
• Maas IW, Boven E, Pinedo HM, The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J Cancer 1991;48:749-56
   PubMed Web of Science ®Google Scholar
• Maccubbin DL, Wing KR, Mace KF, Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992;52:3572-6
   PubMed Web of Science ®Google Scholar
• Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000;49:181-5
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C, A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9
   PubMed Web of Science ®Google Scholar
• Mohebtash M, Tsang KY, Madan RA, A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011;17:7164-73
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-9
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-70
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J, Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31
   PubMed Web of Science ®Google Scholar
• Bilusic M, Gulley J, Heery C, A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011;29(7S):abstract 163
   Google Scholar
• Madan RA, Mohebtash M, Arlen P, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Taback B, Sherman W, Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009;7:2
   PubMed Web of Science ®Google Scholar
• Amato RJ, Hawkins RE, Kaufman HL, Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010;16:5539-47
   PubMed Web of Science ®Google Scholar
• Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012;130:1948-59
   PubMed Web of Science ®Google Scholar
• Farsaci B, Sabzevari H, Higgins JP, Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 2010;127:1603-13
   PubMedGoogle Scholar
• Balachandran VP, Cavnar MJ, Zeng S, Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011;17:1094-100
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P, Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-19
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Chodon T, Sazegar H, The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010;16:6040-8
   PubMed Web of Science ®Google Scholar
• Li Z, Qiao Y, Liu B, Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005;11:4460-8
   PubMed Web of Science ®Google Scholar
• Smith BD, Kasamon YL, Kowalski J, K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010;16:338-47
   PubMed Web of Science ®Google Scholar
• Morse M, Niedzwiecki D, Marshall JL, Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. J Clin Oncol 2011;29:abstract 3557
   Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005;23:2379-87
   PubMed Web of Science ®Google Scholar
• Vaccinogen Clinical Trials: Proof of Efficacy. Available from: http://www.vaccinogeninc.com/vaccinogen/clinical-trials/ [Cited October 2011]
   Google Scholar
• Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-17
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley J, Fojo T, Dahut W. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010;15:969-75
   PubMed Web of Science ®Google Scholar
• Stein WD, Gulley JL, Schlom J, Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-17
   PubMed Web of Science ®Google Scholar
• Klein E, Falzarano S, Maddala T, Use of quantitative gene expression in primary and highest Gleason pattern cancers to identify genes associated with clinical recurrence after radical prostatectomy. J Clin Oncol 2011;29(7S):abstract 39
   Google Scholar
• Conry RM, Khazaeli MB, Saleh MN, Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999;5:2330-7
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hawkins MJ, Tsang KY, Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332-7
   PubMed Web of Science ®Google Scholar
• von Mehren M, Arlen P, Gulley J, The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91
   PubMed Web of Science ®Google Scholar
• Schuetz T, Kaufman H, Marshall JL, Safran H. Extended survival in second-line pancreatic cancer after therapeutic vaccination. J Clin Oncol 2005;23(16S):abstract 2576
   Google Scholar
• Therion's Panvac-VF Misses Endpoint in Pancreatic Cancer. Available from: http://www.allbusiness.com/pharmaceuticals-biotechnology/pharmaceutical/13399572-1.html [Cited October 2011]
   Google Scholar
• Vaccine Therapy and GM-CSF in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer that cannot be Removed by Surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT00669734 [Cited February 2012]
   Google Scholar
• Heery C, Pinto P, Schlom J, Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. J Clin Oncol 2011;29:abstract 2530
   Google Scholar
• DiPaola RS, Chen Y, Bubley G, A phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802 [abstract 108]. ASCO Genitourinary Cancers Symposium 2009
   Google Scholar